Get startedLog in
    Picture of Sensorion SA logo

    ALSEN — Sensorion SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Sensorion: Approval For Amended Phase 2A Proof Of Concept Trial Of Sens-401 In Cisplatin-Induced Ototoxicity In France

    Picture of Sensorion SA logoSensorion SA
    24/10/2022 06:34
    Oct 24 (Reuters) - Sensorion SA  ALSEN.PA :
    * SENSORION ANNOUNCES APPROVAL TO INITIATE AMENDED PHASE 2A
PROOF
OF CONCEPT CLINICAL TRIAL OF SENS-401 IN CISPLATIN-INDUCED
OTOTOXICITY IN FRANCE
    * FIRST PATIENT ENROLMENT IS EXPECTED BY END OF 2022

Source text for Eikon:  ID:nBw60nWS9a 
Further company coverage:  ALSEN.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Sensorion SA

    See all news